hydroxyurea has been researched along with Hemolysis in 41 studies
Hemolysis: The destruction of ERYTHROCYTES by many different causal agents such as antibodies, bacteria, chemicals, temperature, and changes in tonicity.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Intravascular hemolysis (IH) contributes to the development of endothelial dysfunction (ED) in sickle cell anemia (SCA), and the effects of hydroxyurea (HU, the only approved drug that decreases the frequency and severity of vaso-oclussive crises) on IH and ED in SCA remain unclear." | 8.02 | Effect of hydroxyurea therapy on intravascular hemolysis and endothelial dysfunction markers in sickle cell anemia patients. ( Alagbe, AE; Araújo, ADS; Arcanjo, GDS; Batista, THC; Bezerra, MAC; Chenou, F; Costa, FF; De Paula, EV; Domingos, IF; Dos Santos, MNN; Hounkpe, BW; Lucena-Araújo, AR; Santana, RM; Sonati, MF; Tonassé, WV, 2021) |
| " The aim of this study was to characterize TG at the individual level and assess its relationship with age, hemolysis, transcranial Doppler velocity (TCD), and hydroxyurea treatment." | 7.79 | Thrombin generation in children with sickle cell disease: relationship with age, hemolysis, transcranial Doppler velocity, and hydroxyurea treatment. ( Demulder, A; Ferster, A; Lê, PQ; Noubouossie, DC; Rozen, L; Willems, D; Ziereisen, F, 2013) |
| " Higher Epo levels were seen in patients receiving hydroxyurea (HU), but no correlation with oxygenation, hemolysis, renal function, or inflammation was observed." | 5.19 | Erythropoietin levels in patients with sickle cell disease do not correlate with known inducers of erythropoietin. ( Ballas, SK; Caro, J; McKenzie, SE; Pulte, ED, 2014) |
| "Hydroxyurea therapy reduces hemolysis and decreases serum bilirubin levels in children and adults with sickle cell anemia (SCA) and may therefore help prevent the development of cholelithiasis in this patient population." | 5.10 | UGT1A promoter polymorphisms influence bilirubin response to hydroxyurea therapy in sickle cell anemia. ( Heeney, MM; Howard, TA; Ware, RE; Zimmerman, SA, 2003) |
| "Intravascular hemolysis (IH) contributes to the development of endothelial dysfunction (ED) in sickle cell anemia (SCA), and the effects of hydroxyurea (HU, the only approved drug that decreases the frequency and severity of vaso-oclussive crises) on IH and ED in SCA remain unclear." | 4.02 | Effect of hydroxyurea therapy on intravascular hemolysis and endothelial dysfunction markers in sickle cell anemia patients. ( Alagbe, AE; Araújo, ADS; Arcanjo, GDS; Batista, THC; Bezerra, MAC; Chenou, F; Costa, FF; De Paula, EV; Domingos, IF; Dos Santos, MNN; Hounkpe, BW; Lucena-Araújo, AR; Santana, RM; Sonati, MF; Tonassé, WV, 2021) |
| "SCD patients, in steady state and asymptomatic for pulmonary hypertension, were studied stressing on hydroxyurea therapy, serum ferritin, urinary albumin creatinine ratio (UACR), high-sensitivity C-reactive protein (hs-CRP) and sFas/sFasL levels." | 3.83 | Soluble Fas/FasL ratio as a marker of vasculopathy in children and adolescents with sickle cell disease. ( Adly, AA; Andrawes, NG; Eladawy, R; Ismail, EA; Mahmoud, MM, 2016) |
| " The aim of this study was to characterize TG at the individual level and assess its relationship with age, hemolysis, transcranial Doppler velocity (TCD), and hydroxyurea treatment." | 3.79 | Thrombin generation in children with sickle cell disease: relationship with age, hemolysis, transcranial Doppler velocity, and hydroxyurea treatment. ( Demulder, A; Ferster, A; Lê, PQ; Noubouossie, DC; Rozen, L; Willems, D; Ziereisen, F, 2013) |
| " It appears to be a complication of chronic hemolysis, is resistant to hydroxyurea therapy, and confers a high risk of death." | 3.72 | Pulmonary hypertension as a risk factor for death in patients with sickle cell disease. ( Blackwelder, WC; Brown, B; Castro, O; Coles, WA; Ernst, I; Gladwin, MT; Hunter, LA; Jison, ML; Minter, K; Nichols, JS; Ognibene, FP; Plehn, JF; Rodgers, GP; Sachdev, V; Schechter, AN; Shizukuda, Y, 2004) |
| "This study confirms that hydroxyurea therapy increases hemoglobin F production and provides objective evidence that hydroxyurea reduces the rate of hemolysis and intracellular polymerization of hemoglobin S." | 3.68 | Treatment of sickle cell anemia with hydroxyurea and erythropoietin. ( Brugnara, C; Bunn, HF; Charache, S; Dover, GJ; Goldberg, MA; Schapira, L, 1990) |
| "Sickle cell disease is a common and life-threatening haematological disorder that affects millions of people worldwide." | 2.55 | Sickle cell disease. ( Abboud, MR; de Montalembert, M; Tshilolo, L; Ware, RE, 2017) |
| " Accordingly, we conclude that clinical trials in SCD designed to increase the bioavailability of NO or association studies in which SCD clinical manifestations are related to plasma hemoglobin via its surrogates should be viewed with caution." | 2.46 | Pulmonary hypertension and nitric oxide depletion in sickle cell disease. ( Bunn, HF; Dover, GJ; Hebbel, RP; Nathan, DG; Platt, OS; Rosse, WF; Ware, RE, 2010) |
| "Treatment with hydroxyurea is usually considered for patients with recurrent vaso-occlusive events, but additional indications for treatment may include laboratory markers of disease severity and evidence of chronic organ dysfunction." | 2.45 | Advances in the use of hydroxyurea. ( Aygun, B; Ware, RE, 2009) |
| " The participation of nitric oxide (NO) in oxidative reactions causes a reduction in NO bioavailability and contributes to vascular dysfunction in SCD." | 2.44 | Redox-dependent impairment of vascular function in sickle cell disease. ( Aslan, M; Freeman, BA, 2007) |
| "Hydroxyurea treatment lowered TNF-induced VCAM1 and NOS3 expression but did not affect heme-induced HMOX1 expression." | 1.72 | VCAM1, HMOX1 and NOS3 differential endothelial expression may impact sickle cell anemia vasculopathy. ( Coelho, A; Faustino, P; Silva, M; Vargas, S, 2022) |
| "Hydroxyurea-treated patients had higher apelin levels than untreated ones (P=0." | 1.43 | Serum apelin as a novel non-invasive marker for subclinical cardiopulmonary complications in children and adolescents with sickle cell disease. ( Elbarbary, NS; Fahmy, E; Ismail, EA; Roushdy, A, 2016) |
| "Hemolysis and consequent release of cell-free hemoglobin (CFHb) impair vascular nitric oxide (NO) bioavailability and cause oxidative and inflammatory processes." | 1.42 | Acute hemolytic vascular inflammatory processes are prevented by nitric oxide replacement or a single dose of hydroxyurea. ( Almeida, CB; Conran, N; Costa, FF; Costa, FT; Covas, DT; Leonardo, FC; Souza, LE; Werneck, CC, 2015) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (2.44) | 18.7374 |
| 1990's | 1 (2.44) | 18.2507 |
| 2000's | 10 (24.39) | 29.6817 |
| 2010's | 22 (53.66) | 24.3611 |
| 2020's | 7 (17.07) | 2.80 |
| Authors | Studies |
|---|---|
| Silva, M | 1 |
| Coelho, A | 1 |
| Vargas, S | 1 |
| Faustino, P | 1 |
| Ginete, C | 1 |
| Delgadinho, M | 1 |
| Santos, B | 1 |
| Pinto, V | 1 |
| Silva, C | 1 |
| Miranda, A | 1 |
| Brito, M | 1 |
| D'Alessandro, A | 1 |
| Nouraie, SM | 1 |
| Zhang, Y | 2 |
| Cendali, F | 1 |
| Gamboni, F | 1 |
| Reisz, JA | 1 |
| Zhang, X | 1 |
| Bartsch, KW | 1 |
| Galbraith, MD | 1 |
| Espinosa, JM | 1 |
| Gordeuk, VR | 4 |
| Gladwin, MT | 5 |
| Fogarty, H | 1 |
| Ahmad, A | 1 |
| Atiq, F | 1 |
| Doherty, D | 1 |
| Ward, S | 1 |
| Karampini, E | 1 |
| Rehill, A | 1 |
| Leon, G | 1 |
| Byrne, C | 1 |
| Geoghegan, R | 1 |
| Conroy, H | 1 |
| Byrne, M | 1 |
| Budde, U | 1 |
| Schneppenheim, S | 1 |
| Sheehan, C | 1 |
| Ngwenya, N | 1 |
| Baker, RI | 1 |
| Preston, RJS | 1 |
| Tuohy, E | 1 |
| McMahon, C | 1 |
| O'Donnell, JS | 1 |
| Roumenina, LT | 1 |
| Chadebech, P | 1 |
| Bodivit, G | 1 |
| Vieira-Martins, P | 1 |
| Grunenwald, A | 1 |
| Boudhabhay, I | 1 |
| Poillerat, V | 1 |
| Pakdaman, S | 1 |
| Kiger, L | 1 |
| Jouard, A | 1 |
| Audureau, E | 1 |
| Pirenne, F | 1 |
| Galactéros, F | 1 |
| Frémeaux-Bacchi, V | 1 |
| Bartolucci, P | 1 |
| Ataga, KI | 2 |
| Staffa, SJ | 1 |
| Brugnara, C | 2 |
| Stocker, JW | 1 |
| Chenou, F | 1 |
| Hounkpe, BW | 1 |
| Domingos, IF | 1 |
| Tonassé, WV | 1 |
| Batista, THC | 1 |
| Santana, RM | 1 |
| Arcanjo, GDS | 1 |
| Alagbe, AE | 1 |
| Araújo, ADS | 1 |
| Lucena-Araújo, AR | 1 |
| Bezerra, MAC | 1 |
| Costa, FF | 2 |
| Sonati, MF | 1 |
| De Paula, EV | 1 |
| Dos Santos, MNN | 1 |
| Piccin, A | 1 |
| Murphy, C | 1 |
| Eakins, E | 1 |
| Rondinelli, MB | 1 |
| Daves, M | 1 |
| Vecchiato, C | 1 |
| Wolf, D | 1 |
| Mc Mahon, C | 1 |
| Smith, OP | 1 |
| Vichinsky, E | 1 |
| Hoppe, CC | 1 |
| Ware, RE | 5 |
| Nduba, V | 1 |
| El-Beshlawy, A | 1 |
| Hassab, H | 1 |
| Achebe, MM | 1 |
| Alkindi, S | 1 |
| Brown, RC | 1 |
| Diuguid, DL | 1 |
| Telfer, P | 1 |
| Tsitsikas, DA | 1 |
| Elghandour, A | 1 |
| Kanter, J | 1 |
| Abboud, MR | 2 |
| Lehrer-Graiwer, J | 1 |
| Tonda, M | 1 |
| Intondi, A | 1 |
| Tong, B | 1 |
| Howard, J | 1 |
| Noubouossie, DC | 1 |
| Lê, PQ | 1 |
| Rozen, L | 1 |
| Ziereisen, F | 1 |
| Willems, D | 1 |
| Demulder, A | 1 |
| Ferster, A | 1 |
| Tantawy, AA | 1 |
| Adly, AA | 2 |
| Ismail, EA | 3 |
| Darwish, YW | 1 |
| Ali Zedan, M | 1 |
| Pulte, ED | 1 |
| McKenzie, SE | 1 |
| Caro, J | 1 |
| Ballas, SK | 1 |
| Field, JJ | 1 |
| Nathan, DG | 2 |
| Almeida, CB | 1 |
| Souza, LE | 1 |
| Leonardo, FC | 1 |
| Costa, FT | 1 |
| Werneck, CC | 1 |
| Covas, DT | 1 |
| Conran, N | 1 |
| Mecabo, G | 1 |
| Yamamoto, M | 1 |
| Biassi, TP | 1 |
| Figueiredo, MS | 1 |
| Quimby, KR | 1 |
| Hambleton, IR | 1 |
| Landis, RC | 1 |
| Andrawes, NG | 1 |
| Mahmoud, MM | 1 |
| Eladawy, R | 1 |
| Elbarbary, NS | 1 |
| Roushdy, A | 1 |
| Fahmy, E | 1 |
| Okumura, JV | 1 |
| Silva, DG | 1 |
| Torres, LS | 1 |
| Belini-Junior, E | 1 |
| Barberino, WM | 1 |
| Oliveira, RG | 1 |
| Carrocini, GC | 1 |
| Gelaleti, GB | 1 |
| Lobo, CL | 1 |
| Bonini-Domingos, CR | 1 |
| Brandow, AM | 1 |
| Wandersee, NJ | 1 |
| Dasgupta, M | 1 |
| Hoffmann, RG | 1 |
| Hillery, CA | 1 |
| Stucky, CL | 1 |
| Panepinto, JA | 1 |
| Indik, JH | 1 |
| Nair, V | 1 |
| Rafikov, R | 1 |
| Nyotowidjojo, IS | 1 |
| Bisla, J | 1 |
| Kansal, M | 1 |
| Parikh, DS | 1 |
| Robinson, M | 1 |
| Desai, A | 1 |
| Oberoi, M | 1 |
| Gupta, A | 1 |
| Abbasi, T | 1 |
| Khalpey, Z | 1 |
| Patel, AR | 1 |
| Lang, RM | 1 |
| Dudley, SC | 1 |
| Choi, BR | 1 |
| Garcia, JG | 1 |
| Machado, RF | 1 |
| Desai, AA | 1 |
| Lovato, S | 1 |
| Ayto, R | 1 |
| de Montalembert, M | 1 |
| Tshilolo, L | 1 |
| Olnes, M | 1 |
| Chi, A | 1 |
| Haney, C | 1 |
| May, R | 1 |
| Minniti, C | 1 |
| Taylor, J | 1 |
| Kato, GJ | 3 |
| Aygun, B | 1 |
| Bunn, HF | 2 |
| Dover, GJ | 2 |
| Hebbel, RP | 1 |
| Platt, OS | 1 |
| Rosse, WF | 1 |
| Nouraie, M | 2 |
| Reading, NS | 1 |
| Campbell, A | 1 |
| Minniti, CP | 1 |
| Rana, SR | 1 |
| Luchtman-Jones, L | 1 |
| Castro, OL | 1 |
| Prchal, JT | 1 |
| Rees, DC | 2 |
| Williams, TN | 1 |
| Moller, HJ | 1 |
| Nielsen, MJ | 1 |
| Bartram, J | 1 |
| Dick, MC | 1 |
| Height, SE | 1 |
| Moestrup, SK | 1 |
| Connes, P | 1 |
| Machado, R | 1 |
| Hue, O | 1 |
| Reid, H | 1 |
| Novelli, EM | 1 |
| Ragni, MV | 1 |
| Hildesheim, ME | 1 |
| Barge, S | 1 |
| Meyer, MP | 1 |
| Hassett, AC | 1 |
| Isenberg, JS | 1 |
| Ohashi, N | 1 |
| Yonemura, K | 1 |
| Sugiura, T | 1 |
| Isozaki, T | 1 |
| Togawa, A | 1 |
| Fujigaki, Y | 1 |
| Yamamoto, T | 1 |
| Hishida, A | 1 |
| Heeney, MM | 1 |
| Howard, TA | 1 |
| Zimmerman, SA | 1 |
| Sachdev, V | 1 |
| Jison, ML | 1 |
| Shizukuda, Y | 1 |
| Plehn, JF | 1 |
| Minter, K | 1 |
| Brown, B | 1 |
| Coles, WA | 1 |
| Nichols, JS | 1 |
| Ernst, I | 1 |
| Hunter, LA | 1 |
| Blackwelder, WC | 1 |
| Schechter, AN | 1 |
| Rodgers, GP | 1 |
| Castro, O | 1 |
| Ognibene, FP | 1 |
| Schnog, JB | 1 |
| Duits, AJ | 1 |
| Muskiet, FA | 1 |
| ten Cate, H | 1 |
| Rojer, RA | 1 |
| Brandjes, DP | 1 |
| Wood, KC | 1 |
| Granger, DN | 1 |
| Aslan, M | 1 |
| Freeman, BA | 1 |
| Rezaei Kalantari, H | 1 |
| Al-Jam'a, AH | 1 |
| Al-Dabbous, IA | 1 |
| Goldberg, MA | 1 |
| Schapira, L | 1 |
| Charache, S | 1 |
| Byfield, P | 1 |
| Sercarz, E | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase 3, Double-blind, Randomized, Placebo-controlled, Multicenter Study of Voxelotor Administered Orally to Patients With Sickle Cell Disease[NCT03036813] | Phase 3 | 449 participants (Actual) | Interventional | 2016-12-31 | Completed | ||
| Assessing Functional Capacity in Sickle Cell Patients Receiving Voxelotor[NCT06023199] | 10 participants (Anticipated) | Observational | 2023-10-23 | Recruiting | |||
| Comparison of Efficacy Between Bilateral Superficial Cervical Plexus Block and Local Infiltration of Lidocaine 2% in Patients Undergoing Tracheostomy[NCT04006639] | 36 participants (Actual) | Interventional | 2019-08-01 | Completed | |||
| Safety and Feasibility of High-Dose Topical Capsaicin for the Treatment of Neuropathic Pain in Pediatric Sickle Cell Disease[NCT03899246] | Phase 1 | 10 participants (Actual) | Interventional | 2019-07-03 | Completed | ||
| A Pilot Study of the Use of Oral Ketamine for Treatment of Vaso-Occlusive Pain in Adolescents and Young Adults[NCT05378555] | Phase 3 | 10 participants (Anticipated) | Interventional | 2023-05-01 | Recruiting | ||
| Prospective Clinical Study on Early Inflammatory, Cell Adhesion and Hemostatic Plasmatic Markers of Endothelial Dysfunction in Children With Sickle Cell Disease (SCD)[NCT04839159] | 41 participants (Anticipated) | Interventional | 2012-05-10 | Active, not recruiting | |||
| Studies of the Natural History of Sickle Cell Disease[NCT00081523] | 3,500 participants (Anticipated) | Observational | 2004-04-29 | Recruiting | |||
| A Substudy of the CADRE Study: Determination of Clinical Markers in Patients With Extreme Sickle Cell Disease Phenotype[NCT03352986] | 300 participants (Anticipated) | Observational | 2017-05-15 | Recruiting | |||
| Aerobic Physical Fitness and Health-related Quality of Life in Children With Sickle Cell Disease.[NCT05995743] | 72 participants (Actual) | Observational | 2021-11-01 | Completed | |||
| Evaluation of the Hemostatic Potential in Sickle Cell Disease Patients[NCT02565082] | 64 participants (Actual) | Interventional | 2015-09-30 | Completed | |||
| Evaluation of Impact of Disease on Quality of Life, Education and Socio-professional Integration of Adults and Parents of Children Living With Sickle- Cell Disease in France[NCT04413539] | 1,088 participants (Actual) | Observational | 2020-06-02 | Completed | |||
| Treatment With Hydoxycarbamide and L-Carnitine in Adult Patients With Severe Forms of Sickle Cell Anemia: An Overview[NCT05081349] | Phase 4 | 91 participants (Actual) | Interventional | 2017-01-10 | Completed | ||
| Evaluation of Sickle Cell Liver Disease[NCT01950429] | 42 participants (Actual) | Observational | 2013-10-16 | Completed | |||
| Low Dose Aspirin for Preventing Intrauterine Growth Restriction and Preeclampsia in Sickle Cell Pregnancy (PIPSICKLE): a Randomized Controlled Trial[NCT05253781] | Phase 3 | 476 participants (Anticipated) | Interventional | 2020-07-01 | Recruiting | ||
| National Transfusion Treatment Survey in Patients With Sickle Cell Disease (SCD)[NCT03397017] | 200 participants (Actual) | Observational | 2016-07-01 | Completed | |||
| Macrolide Therapy to Improve Forced Expiratory Volume in 1 Second in Adults With Sickle Cell Disease: a Feasibility Trial[NCT02960503] | Phase 1/Phase 2 | 0 participants (Actual) | Interventional | 2016-09-30 | Withdrawn (stopped due to Key personnel moved to new location. Therefore, we had insufficient resources to initiate the trial.) | ||
| Long-Term, Open-Label, Multicenter, Extension Study of Bosentan in Patients With Pulmonary Hypertension Associated With Sickle Cell Disease Completing a Double-Blind ASSET Study (AC-052-368 or AC 052-369)[NCT00360087] | Phase 3 | 236 participants | Interventional | 2006-03-31 | Terminated (stopped due to Slow enrollment) | ||
| Role of Nitric Oxide Scavenging by Plasma Hemoglobin and Identification of Hemolysis-Associated Pulmonary Hypertension in Malaria[NCT00527163] | 103 participants (Actual) | Observational | 2007-09-04 | Completed | |||
| Serum Brain Natriuretic Peptide Levels and Its Correlation With Echocardiographic Measurements Suggestive of Pulmonary Hypertension in Pediatric Patients With Sickle Cell Disease[NCT01023451] | 21 participants (Actual) | Observational | 2009-12-31 | Completed | |||
| Iron-mediated Vascular Disease in Sickle Cell Disease.[NCT01239901] | 150 participants (Actual) | Observational | 2009-12-31 | Completed | |||
| Erythrocyte Glutamine Level Relation to Pulmonary Hypertension Risk in Beta Thalassemia Major Children in Assiut University Children Hospital[NCT03133169] | 80 participants (Actual) | Observational | 2017-06-01 | Completed | |||
| Heart, Arteries and Sikle Cell Disease, a Multicentric Cohort of Cardiovascular Complications in Subsaharan Africa[NCT03114137] | 4,500 participants (Anticipated) | Observational [Patient Registry] | 2012-03-31 | Recruiting | |||
| An Evaluation of Tricuspid Regurgitant Jet Velocity as an Independent Marker for Mortality in Patients With Sickle Cell Anemia: A Retrospective Data Review[NCT01783093] | 209 participants (Actual) | Observational | 2009-12-31 | Completed | |||
| PINPOINT: Gaming Technology to Engage Adolescent Sickle Cell Patients in Precision Pain Management[NCT03291613] | 13 participants (Actual) | Interventional | 2017-01-15 | Completed | |||
| Interest of Nutritional Care of Children With Sickle Cell Disease on Bone Mineral Density and Body Composition[NCT04754711] | 70 participants (Anticipated) | Interventional | 2021-09-23 | Recruiting | |||
| Evaluation of Potential Synergy of Combining Hydroxyurea With Nitric Oxide Donors on Fetal Hemoglobin Synthesis in Patients With Sickle Cell Anemia[NCT00056433] | Phase 1 | 39 participants (Actual) | Interventional | 2003-03-10 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Number of Vaso-Occlusive Crisis (VOC) events averaged per year. (NCT03036813)
Timeframe: Baseline to Week 72
| Intervention | Events per year (Mean) |
|---|---|
| Voxelotor 900 mg | 2.4 |
| Voxelotor 1500 mg | 2.4 |
| Placebo | 2.8 |
Number of participants with increase in Hb >1 g/dL from Baseline to Week 24 (NCT03036813)
Timeframe: Baseline to Week 24
| Intervention | Participants (Count of Participants) |
|---|---|
| Voxelotor 900 mg | 30 |
| Voxelotor 1500 mg | 46 |
| Placebo | 6 |
Percentage change from Baseline to week 24 in Lactate Dehydrogenase (LDH) (NCT03036813)
Timeframe: Baseline to Week 24
| Intervention | Percentage Change (Least Squares Mean) |
|---|---|
| Voxelotor 900 mg | 1.6 |
| Voxelotor 1500 mg | -4.6 |
| Placebo | 3.0 |
Percentage change from Baseline to week 24 in reticulocytes % which is a % of total Red Blood Cells (RBCs). (NCT03036813)
Timeframe: Baseline to Week 24
| Intervention | Percentage Change (Least Squares Mean) |
|---|---|
| Voxelotor 900 mg | -1.4 |
| Voxelotor 1500 mg | -18.0 |
| Placebo | 6.8 |
Percentage change from Baseline to week 24 in the absolute reticulocyte which is used to estimate the degree of effective erythropoiesis. This values is important in Sickle Cell Disease and was reported by the central laboratory. (NCT03036813)
Timeframe: Baseline to Week 24
| Intervention | percentage change (Least Squares Mean) |
|---|---|
| Voxelotor 900 mg | 4.7 |
| Voxelotor 1500 mg | -6.4 |
| Placebo | 4.7 |
Percentage change from Baseline to week 24 in unconjugated bilirubin (NCT03036813)
Timeframe: Baseline to Week 24
| Intervention | percentage change (Least Squares Mean) |
|---|---|
| Voxelotor 900 mg | -20.1 |
| Voxelotor 1500 mg | -29.1 |
| Placebo | -2.8 |
"Ten likert-type questions assessing user-friendliness of technology. Each question has five answer options that range from Strongly Agree to Strongly Disagree. Scores range from 0-100. A score of 68 or above is considered above average. All scores averaged." (NCT03291613)
Timeframe: After 1-hour usability session
| Intervention | units on a scale (Mean) |
|---|---|
| Pinpoint App | 86.67 |
11 reviews available for hydroxyurea and Hemolysis
| Article | Year |
|---|---|
Insight into the complex pathophysiology of sickle cell anaemia and possible treatment.
Topics: Anemia, Sickle Cell; Animals; Antisickling Agents; beta-Globins; Biomarkers; Blood Coagulation; Cell | 2019 |
Advances in sickle cell therapies in the hydroxyurea era.
Topics: Anemia, Sickle Cell; Animals; Cell Adhesion; Genetic Therapy; Hematopoietic Stem Cell Transplantatio | 2014 |
Sickle cell disease.
Topics: Anemia, Sickle Cell; Antisickling Agents; Blood Transfusion; Cerebrovascular Disorders; Chronic Dise | 2017 |
Sickle cell disease.
Topics: Anemia, Sickle Cell; Antisickling Agents; Blood Transfusion; Cerebrovascular Disorders; Chronic Dise | 2017 |
Sickle cell disease.
Topics: Anemia, Sickle Cell; Antisickling Agents; Blood Transfusion; Cerebrovascular Disorders; Chronic Dise | 2017 |
Sickle cell disease.
Topics: Anemia, Sickle Cell; Antisickling Agents; Blood Transfusion; Cerebrovascular Disorders; Chronic Dise | 2017 |
Advances in the use of hydroxyurea.
Topics: Adult; Anemia, Sickle Cell; Animals; Arterial Occlusive Diseases; Bone Marrow Diseases; Child; Clini | 2009 |
Pulmonary hypertension and nitric oxide depletion in sickle cell disease.
Topics: Adult; Anemia, Sickle Cell; Animals; Child; Clinical Trials as Topic; Disease Models, Animal; Echoca | 2010 |
Sickle-cell disease.
Topics: Acute Chest Syndrome; Africa; Anemia, Sickle Cell; Antisickling Agents; Blood Transfusion; Disease S | 2010 |
Sickle-cell disease.
Topics: Acute Chest Syndrome; Africa; Anemia, Sickle Cell; Antisickling Agents; Blood Transfusion; Disease S | 2010 |
Sickle-cell disease.
Topics: Acute Chest Syndrome; Africa; Anemia, Sickle Cell; Antisickling Agents; Blood Transfusion; Disease S | 2010 |
Sickle-cell disease.
Topics: Acute Chest Syndrome; Africa; Anemia, Sickle Cell; Antisickling Agents; Blood Transfusion; Disease S | 2010 |
Sickle-cell disease.
Topics: Acute Chest Syndrome; Africa; Anemia, Sickle Cell; Antisickling Agents; Blood Transfusion; Disease S | 2010 |
Sickle-cell disease.
Topics: Acute Chest Syndrome; Africa; Anemia, Sickle Cell; Antisickling Agents; Blood Transfusion; Disease S | 2010 |
Sickle-cell disease.
Topics: Acute Chest Syndrome; Africa; Anemia, Sickle Cell; Antisickling Agents; Blood Transfusion; Disease S | 2010 |
Sickle-cell disease.
Topics: Acute Chest Syndrome; Africa; Anemia, Sickle Cell; Antisickling Agents; Blood Transfusion; Disease S | 2010 |
Sickle-cell disease.
Topics: Acute Chest Syndrome; Africa; Anemia, Sickle Cell; Antisickling Agents; Blood Transfusion; Disease S | 2010 |
Sickle-cell disease.
Topics: Acute Chest Syndrome; Africa; Anemia, Sickle Cell; Antisickling Agents; Blood Transfusion; Disease S | 2010 |
Sickle-cell disease.
Topics: Acute Chest Syndrome; Africa; Anemia, Sickle Cell; Antisickling Agents; Blood Transfusion; Disease S | 2010 |
Sickle-cell disease.
Topics: Acute Chest Syndrome; Africa; Anemia, Sickle Cell; Antisickling Agents; Blood Transfusion; Disease S | 2010 |
Sickle-cell disease.
Topics: Acute Chest Syndrome; Africa; Anemia, Sickle Cell; Antisickling Agents; Blood Transfusion; Disease S | 2010 |
Sickle-cell disease.
Topics: Acute Chest Syndrome; Africa; Anemia, Sickle Cell; Antisickling Agents; Blood Transfusion; Disease S | 2010 |
Sickle-cell disease.
Topics: Acute Chest Syndrome; Africa; Anemia, Sickle Cell; Antisickling Agents; Blood Transfusion; Disease S | 2010 |
Sickle-cell disease.
Topics: Acute Chest Syndrome; Africa; Anemia, Sickle Cell; Antisickling Agents; Blood Transfusion; Disease S | 2010 |
Sickle-cell disease.
Topics: Acute Chest Syndrome; Africa; Anemia, Sickle Cell; Antisickling Agents; Blood Transfusion; Disease S | 2010 |
Sickle-cell disease.
Topics: Acute Chest Syndrome; Africa; Anemia, Sickle Cell; Antisickling Agents; Blood Transfusion; Disease S | 2010 |
Sickle-cell disease.
Topics: Acute Chest Syndrome; Africa; Anemia, Sickle Cell; Antisickling Agents; Blood Transfusion; Disease S | 2010 |
Sickle-cell disease.
Topics: Acute Chest Syndrome; Africa; Anemia, Sickle Cell; Antisickling Agents; Blood Transfusion; Disease S | 2010 |
Sickle-cell disease.
Topics: Acute Chest Syndrome; Africa; Anemia, Sickle Cell; Antisickling Agents; Blood Transfusion; Disease S | 2010 |
Sickle-cell disease.
Topics: Acute Chest Syndrome; Africa; Anemia, Sickle Cell; Antisickling Agents; Blood Transfusion; Disease S | 2010 |
Sickle-cell disease.
Topics: Acute Chest Syndrome; Africa; Anemia, Sickle Cell; Antisickling Agents; Blood Transfusion; Disease S | 2010 |
Sickle-cell disease.
Topics: Acute Chest Syndrome; Africa; Anemia, Sickle Cell; Antisickling Agents; Blood Transfusion; Disease S | 2010 |
Sickle-cell disease.
Topics: Acute Chest Syndrome; Africa; Anemia, Sickle Cell; Antisickling Agents; Blood Transfusion; Disease S | 2010 |
Sickle-cell disease.
Topics: Acute Chest Syndrome; Africa; Anemia, Sickle Cell; Antisickling Agents; Blood Transfusion; Disease S | 2010 |
Sickle-cell disease.
Topics: Acute Chest Syndrome; Africa; Anemia, Sickle Cell; Antisickling Agents; Blood Transfusion; Disease S | 2010 |
Sickle-cell disease.
Topics: Acute Chest Syndrome; Africa; Anemia, Sickle Cell; Antisickling Agents; Blood Transfusion; Disease S | 2010 |
Sickle-cell disease.
Topics: Acute Chest Syndrome; Africa; Anemia, Sickle Cell; Antisickling Agents; Blood Transfusion; Disease S | 2010 |
Sickle-cell disease.
Topics: Acute Chest Syndrome; Africa; Anemia, Sickle Cell; Antisickling Agents; Blood Transfusion; Disease S | 2010 |
Sickle-cell disease.
Topics: Acute Chest Syndrome; Africa; Anemia, Sickle Cell; Antisickling Agents; Blood Transfusion; Disease S | 2010 |
Sickle-cell disease.
Topics: Acute Chest Syndrome; Africa; Anemia, Sickle Cell; Antisickling Agents; Blood Transfusion; Disease S | 2010 |
Sickle-cell disease.
Topics: Acute Chest Syndrome; Africa; Anemia, Sickle Cell; Antisickling Agents; Blood Transfusion; Disease S | 2010 |
Sickle-cell disease.
Topics: Acute Chest Syndrome; Africa; Anemia, Sickle Cell; Antisickling Agents; Blood Transfusion; Disease S | 2010 |
Sickle-cell disease.
Topics: Acute Chest Syndrome; Africa; Anemia, Sickle Cell; Antisickling Agents; Blood Transfusion; Disease S | 2010 |
Sickle-cell disease.
Topics: Acute Chest Syndrome; Africa; Anemia, Sickle Cell; Antisickling Agents; Blood Transfusion; Disease S | 2010 |
Sickle-cell disease.
Topics: Acute Chest Syndrome; Africa; Anemia, Sickle Cell; Antisickling Agents; Blood Transfusion; Disease S | 2010 |
Sickle-cell disease.
Topics: Acute Chest Syndrome; Africa; Anemia, Sickle Cell; Antisickling Agents; Blood Transfusion; Disease S | 2010 |
Sickle-cell disease.
Topics: Acute Chest Syndrome; Africa; Anemia, Sickle Cell; Antisickling Agents; Blood Transfusion; Disease S | 2010 |
Sickle-cell disease.
Topics: Acute Chest Syndrome; Africa; Anemia, Sickle Cell; Antisickling Agents; Blood Transfusion; Disease S | 2010 |
Sickle-cell disease.
Topics: Acute Chest Syndrome; Africa; Anemia, Sickle Cell; Antisickling Agents; Blood Transfusion; Disease S | 2010 |
Sickle-cell disease.
Topics: Acute Chest Syndrome; Africa; Anemia, Sickle Cell; Antisickling Agents; Blood Transfusion; Disease S | 2010 |
Sickle-cell disease.
Topics: Acute Chest Syndrome; Africa; Anemia, Sickle Cell; Antisickling Agents; Blood Transfusion; Disease S | 2010 |
Sickle-cell disease.
Topics: Acute Chest Syndrome; Africa; Anemia, Sickle Cell; Antisickling Agents; Blood Transfusion; Disease S | 2010 |
Sickle-cell disease.
Topics: Acute Chest Syndrome; Africa; Anemia, Sickle Cell; Antisickling Agents; Blood Transfusion; Disease S | 2010 |
Sickle-cell disease.
Topics: Acute Chest Syndrome; Africa; Anemia, Sickle Cell; Antisickling Agents; Blood Transfusion; Disease S | 2010 |
Sickle-cell disease.
Topics: Acute Chest Syndrome; Africa; Anemia, Sickle Cell; Antisickling Agents; Blood Transfusion; Disease S | 2010 |
Sickle-cell disease.
Topics: Acute Chest Syndrome; Africa; Anemia, Sickle Cell; Antisickling Agents; Blood Transfusion; Disease S | 2010 |
Sickle-cell disease.
Topics: Acute Chest Syndrome; Africa; Anemia, Sickle Cell; Antisickling Agents; Blood Transfusion; Disease S | 2010 |
Exercise limitation, exercise testing and exercise recommendations in sickle cell anemia.
Topics: Adaptation, Physiological; Anemia, Sickle Cell; Arterial Occlusive Diseases; Bronchial Hyperreactivi | 2011 |
Sickle cell disease; a general overview.
Topics: Anemia, Sickle Cell; Blood Transfusion; Constriction, Pathologic; Hemoglobin, Sickle; Hemolysis; Hum | 2004 |
Sickle cell disease; a general overview.
Topics: Anemia, Sickle Cell; Blood Transfusion; Constriction, Pathologic; Hemoglobin, Sickle; Hemolysis; Hum | 2004 |
Sickle cell disease; a general overview.
Topics: Anemia, Sickle Cell; Blood Transfusion; Constriction, Pathologic; Hemoglobin, Sickle; Hemolysis; Hum | 2004 |
Sickle cell disease; a general overview.
Topics: Anemia, Sickle Cell; Blood Transfusion; Constriction, Pathologic; Hemoglobin, Sickle; Hemolysis; Hum | 2004 |
Sickle cell disease: role of reactive oxygen and nitrogen metabolites.
Topics: Anemia, Sickle Cell; Animals; Antioxidants; Antisickling Agents; Endothelium, Vascular; Enzyme Inhib | 2007 |
Redox-dependent impairment of vascular function in sickle cell disease.
Topics: Anemia, Sickle Cell; Anti-Inflammatory Agents; Anticoagulants; Antioxidants; Biological Availability | 2007 |
[How I treat ... sickle cell anemia: current therapies].
Topics: Anemia, Sickle Cell; Anti-Inflammatory Agents, Non-Steroidal; Anticoagulants; Antisickling Agents; A | 2001 |
5 trials available for hydroxyurea and Hemolysis
| Article | Year |
|---|---|
A Phase 3 Randomized Trial of Voxelotor in Sickle Cell Disease.
Topics: Adolescent; Adult; Anemia, Sickle Cell; Antisickling Agents; Benzaldehydes; Biomarkers; Child; Dose- | 2019 |
A Phase 3 Randomized Trial of Voxelotor in Sickle Cell Disease.
Topics: Adolescent; Adult; Anemia, Sickle Cell; Antisickling Agents; Benzaldehydes; Biomarkers; Child; Dose- | 2019 |
A Phase 3 Randomized Trial of Voxelotor in Sickle Cell Disease.
Topics: Adolescent; Adult; Anemia, Sickle Cell; Antisickling Agents; Benzaldehydes; Biomarkers; Child; Dose- | 2019 |
A Phase 3 Randomized Trial of Voxelotor in Sickle Cell Disease.
Topics: Adolescent; Adult; Anemia, Sickle Cell; Antisickling Agents; Benzaldehydes; Biomarkers; Child; Dose- | 2019 |
Erythropoietin levels in patients with sickle cell disease do not correlate with known inducers of erythropoietin.
Topics: Adult; Aged; Anemia, Sickle Cell; Antisickling Agents; Biomarkers; Erythropoietin; Female; Hemoglobi | 2014 |
Improvement in hemolysis and pulmonary arterial systolic pressure in adult patients with sickle cell disease during treatment with hydroxyurea.
Topics: Adult; Anemia, Sickle Cell; Antisickling Agents; Arginase; Blood Pressure; Disease-Free Survival; Ec | 2009 |
UGT1A promoter polymorphisms influence bilirubin response to hydroxyurea therapy in sickle cell anemia.
Topics: Anemia, Sickle Cell; Antisickling Agents; Bilirubin; Child; Dose-Response Relationship, Drug; Drug A | 2003 |
Hydroxyurea in sickle cell disease patients from Eastern Saudi Arabia.
Topics: Adolescent; Adult; Anemia, Sickle Cell; Antisickling Agents; Child; Female; Hemolysis; Humans; Hydro | 2002 |
25 other studies available for hydroxyurea and Hemolysis
| Article | Year |
|---|---|
VCAM1, HMOX1 and NOS3 differential endothelial expression may impact sickle cell anemia vasculopathy.
Topics: Anemia, Sickle Cell; Child; Haplotypes; Heme Oxygenase-1; Hemolysis; Humans; Hydroxyurea; Nitric Oxi | 2022 |
Are Genetic Modifiers the Answer to Different Responses to Hydroxyurea Treatment?-A Pharmacogenetic Study in Sickle Cell Anemia Angolan Children.
Topics: Anemia, Sickle Cell; Fetal Hemoglobin; Hemolysis; Humans; Hydroxyurea; Pharmacogenomic Testing | 2023 |
Metabolic signatures of cardiorenal dysfunction in plasma from sickle cell patients as a function of therapeutic transfusion and hydroxyurea treatment.
Topics: Anemia, Sickle Cell; Bile Acids and Salts; Hemoglobin SC Disease; Hemoglobin, Sickle; Hemolysis; Hum | 2023 |
VWF-ADAMTS13 axis dysfunction in children with sickle cell disease treated with hydroxycarbamide vs blood transfusion.
Topics: ADAMTS13 Protein; Anemia, Sickle Cell; Blood Transfusion; Child; Hemolysis; Hemostatics; Humans; Hyd | 2023 |
Complement activation in sickle cell disease: Dependence on cell density, hemolysis and modulation by hydroxyurea therapy.
Topics: Adolescent; Adult; Anemia, Sickle Cell; Cell Count; Complement Activation; Female; Hemolysis; Humans | 2020 |
Haemoglobin response to senicapoc in patients with sickle cell disease: a re-analysis of the Phase III trial.
Topics: Acetamides; Anemia, Sickle Cell; Benzaldehydes; Clinical Trials, Phase III as Topic; Drug Therapy, C | 2021 |
Effect of hydroxyurea therapy on intravascular hemolysis and endothelial dysfunction markers in sickle cell anemia patients.
Topics: ADAMTS13 Protein; Adolescent; Adult; Anemia, Sickle Cell; Antigens, CD; Antigens, Differentiation, M | 2021 |
Thrombin generation in children with sickle cell disease: relationship with age, hemolysis, transcranial Doppler velocity, and hydroxyurea treatment.
Topics: Adolescent; Age Factors; Anemia, Sickle Cell; Blood Platelets; Child; Child, Preschool; Female; Hemo | 2013 |
Growth differentiation factor-15 in young sickle cell disease patients: relation to hemolysis, iron overload and vascular complications.
Topics: Adolescent; Anemia, Sickle Cell; Antisickling Agents; beta-Thalassemia; Blood Vessels; Case-Control | 2014 |
Acute hemolytic vascular inflammatory processes are prevented by nitric oxide replacement or a single dose of hydroxyurea.
Topics: Anemia, Sickle Cell; Animals; Cell Movement; Cyclic N-Oxides; Disease Models, Animal; Free Radical S | 2015 |
Lactate dehydrogenase isoenzyme 3 and hemolysis in sickle cell anemia: a possible correlation?
Topics: Adult; Anemia, Sickle Cell; Antisickling Agents; Biomarkers; Child, Preschool; Female; Hemolysis; Hu | 2015 |
Intravenous infusion of haptoglobin for the prevention of adverse clinical outcome in Sickle Cell Disease.
Topics: Albuminuria; Anemia, Sickle Cell; Anti-Inflammatory Agents; Antigens, CD; Antigens, Differentiation, | 2015 |
Soluble Fas/FasL ratio as a marker of vasculopathy in children and adolescents with sickle cell disease.
Topics: Adolescent; Albuminuria; Anemia, Sickle Cell; Antisickling Agents; Apoptosis; Biomarkers; C-Reactive | 2016 |
Serum apelin as a novel non-invasive marker for subclinical cardiopulmonary complications in children and adolescents with sickle cell disease.
Topics: Adolescent; Anemia, Sickle Cell; Antisickling Agents; Apelin; Arterial Pressure; Bilirubin; Biomarke | 2016 |
Inheritance of the Bantu/Benin haplotype causes less severe hemolytic and oxidative stress in sickle cell anemia patients treated with hydroxycarbamide.
Topics: Adolescent; Adult; Anemia, Sickle Cell; Antisickling Agents; Biomarkers; Child; Female; Genetic Asso | 2016 |
Substance P is increased in patients with sickle cell disease and associated with haemolysis and hydroxycarbamide use.
Topics: Adolescent; Adult; Anemia, Sickle Cell; Antisickling Agents; Biomarkers; Black or African American; | 2016 |
Substance P is increased in patients with sickle cell disease and associated with haemolysis and hydroxycarbamide use.
Topics: Adolescent; Adult; Anemia, Sickle Cell; Antisickling Agents; Biomarkers; Black or African American; | 2016 |
Substance P is increased in patients with sickle cell disease and associated with haemolysis and hydroxycarbamide use.
Topics: Adolescent; Adult; Anemia, Sickle Cell; Antisickling Agents; Biomarkers; Black or African American; | 2016 |
Substance P is increased in patients with sickle cell disease and associated with haemolysis and hydroxycarbamide use.
Topics: Adolescent; Adult; Anemia, Sickle Cell; Antisickling Agents; Biomarkers; Black or African American; | 2016 |
Associations of Prolonged QTc in Sickle Cell Disease.
Topics: Adult; Anemia, Sickle Cell; Aspartate Aminotransferases; Cohort Studies; Death, Sudden, Cardiac; Ech | 2016 |
Haemolysis in female patient with chronic phase CML.
Topics: Asian People; Blood Transfusion; Female; Hemolysis; Humans; Hydroxyurea; Leukapheresis; Leukemia, My | 2017 |
Association of G6PD with lower haemoglobin concentration but not increased haemolysis in patients with sickle cell anaemia.
Topics: Adolescent; Alleles; alpha-Thalassemia; Anemia, Sickle Cell; Antisickling Agents; Child; Child, Pres | 2010 |
Soluble CD163 levels in children with sickle cell disease.
Topics: Adolescent; Anemia, Sickle Cell; Antigens, CD; Antigens, Differentiation, Myelomonocytic; Antisickli | 2011 |
Plasma thrombospondin-1 is increased during acute sickle cell vaso-occlusive events and associated with acute chest syndrome, hydroxyurea therapy, and lower hemolytic rates.
Topics: Acute Chest Syndrome; Adult; Anemia, Sickle Cell; Antisickling Agents; Biomarkers; Cohort Studies; F | 2012 |
Withdrawal of interferon-alpha results in prompt resolution of thrombocytopenia and hemolysis but not renal failure in hemolytic uremic syndrome caused by interferon-alpha.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Hemolysis; Hemolytic-Uremic Syndrome; Humans; | 2003 |
Pulmonary hypertension as a risk factor for death in patients with sickle cell disease.
Topics: Adult; Anemia, Sickle Cell; Antisickling Agents; Blood Pressure; Cause of Death; Drug Resistance; Ec | 2004 |
Pulmonary hypertension as a risk factor for death in patients with sickle cell disease.
Topics: Adult; Anemia, Sickle Cell; Antisickling Agents; Blood Pressure; Cause of Death; Drug Resistance; Ec | 2004 |
Pulmonary hypertension as a risk factor for death in patients with sickle cell disease.
Topics: Adult; Anemia, Sickle Cell; Antisickling Agents; Blood Pressure; Cause of Death; Drug Resistance; Ec | 2004 |
Pulmonary hypertension as a risk factor for death in patients with sickle cell disease.
Topics: Adult; Anemia, Sickle Cell; Antisickling Agents; Blood Pressure; Cause of Death; Drug Resistance; Ec | 2004 |
Pulmonary hypertension as a risk factor for death in patients with sickle cell disease.
Topics: Adult; Anemia, Sickle Cell; Antisickling Agents; Blood Pressure; Cause of Death; Drug Resistance; Ec | 2004 |
Pulmonary hypertension as a risk factor for death in patients with sickle cell disease.
Topics: Adult; Anemia, Sickle Cell; Antisickling Agents; Blood Pressure; Cause of Death; Drug Resistance; Ec | 2004 |
Pulmonary hypertension as a risk factor for death in patients with sickle cell disease.
Topics: Adult; Anemia, Sickle Cell; Antisickling Agents; Blood Pressure; Cause of Death; Drug Resistance; Ec | 2004 |
Pulmonary hypertension as a risk factor for death in patients with sickle cell disease.
Topics: Adult; Anemia, Sickle Cell; Antisickling Agents; Blood Pressure; Cause of Death; Drug Resistance; Ec | 2004 |
Pulmonary hypertension as a risk factor for death in patients with sickle cell disease.
Topics: Adult; Anemia, Sickle Cell; Antisickling Agents; Blood Pressure; Cause of Death; Drug Resistance; Ec | 2004 |
Pulmonary hypertension as a risk factor for death in patients with sickle cell disease.
Topics: Adult; Anemia, Sickle Cell; Antisickling Agents; Blood Pressure; Cause of Death; Drug Resistance; Ec | 2004 |
Pulmonary hypertension as a risk factor for death in patients with sickle cell disease.
Topics: Adult; Anemia, Sickle Cell; Antisickling Agents; Blood Pressure; Cause of Death; Drug Resistance; Ec | 2004 |
Pulmonary hypertension as a risk factor for death in patients with sickle cell disease.
Topics: Adult; Anemia, Sickle Cell; Antisickling Agents; Blood Pressure; Cause of Death; Drug Resistance; Ec | 2004 |
Pulmonary hypertension as a risk factor for death in patients with sickle cell disease.
Topics: Adult; Anemia, Sickle Cell; Antisickling Agents; Blood Pressure; Cause of Death; Drug Resistance; Ec | 2004 |
Pulmonary hypertension as a risk factor for death in patients with sickle cell disease.
Topics: Adult; Anemia, Sickle Cell; Antisickling Agents; Blood Pressure; Cause of Death; Drug Resistance; Ec | 2004 |
Pulmonary hypertension as a risk factor for death in patients with sickle cell disease.
Topics: Adult; Anemia, Sickle Cell; Antisickling Agents; Blood Pressure; Cause of Death; Drug Resistance; Ec | 2004 |
Pulmonary hypertension as a risk factor for death in patients with sickle cell disease.
Topics: Adult; Anemia, Sickle Cell; Antisickling Agents; Blood Pressure; Cause of Death; Drug Resistance; Ec | 2004 |
Pulmonary hypertension as a risk factor for death in patients with sickle cell disease.
Topics: Adult; Anemia, Sickle Cell; Antisickling Agents; Blood Pressure; Cause of Death; Drug Resistance; Ec | 2004 |
Pulmonary hypertension as a risk factor for death in patients with sickle cell disease.
Topics: Adult; Anemia, Sickle Cell; Antisickling Agents; Blood Pressure; Cause of Death; Drug Resistance; Ec | 2004 |
Pulmonary hypertension as a risk factor for death in patients with sickle cell disease.
Topics: Adult; Anemia, Sickle Cell; Antisickling Agents; Blood Pressure; Cause of Death; Drug Resistance; Ec | 2004 |
Pulmonary hypertension as a risk factor for death in patients with sickle cell disease.
Topics: Adult; Anemia, Sickle Cell; Antisickling Agents; Blood Pressure; Cause of Death; Drug Resistance; Ec | 2004 |
Pulmonary hypertension as a risk factor for death in patients with sickle cell disease.
Topics: Adult; Anemia, Sickle Cell; Antisickling Agents; Blood Pressure; Cause of Death; Drug Resistance; Ec | 2004 |
Pulmonary hypertension as a risk factor for death in patients with sickle cell disease.
Topics: Adult; Anemia, Sickle Cell; Antisickling Agents; Blood Pressure; Cause of Death; Drug Resistance; Ec | 2004 |
Pulmonary hypertension as a risk factor for death in patients with sickle cell disease.
Topics: Adult; Anemia, Sickle Cell; Antisickling Agents; Blood Pressure; Cause of Death; Drug Resistance; Ec | 2004 |
Pulmonary hypertension as a risk factor for death in patients with sickle cell disease.
Topics: Adult; Anemia, Sickle Cell; Antisickling Agents; Blood Pressure; Cause of Death; Drug Resistance; Ec | 2004 |
Pulmonary hypertension as a risk factor for death in patients with sickle cell disease.
Topics: Adult; Anemia, Sickle Cell; Antisickling Agents; Blood Pressure; Cause of Death; Drug Resistance; Ec | 2004 |
Pulmonary hypertension as a risk factor for death in patients with sickle cell disease.
Topics: Adult; Anemia, Sickle Cell; Antisickling Agents; Blood Pressure; Cause of Death; Drug Resistance; Ec | 2004 |
Pulmonary hypertension as a risk factor for death in patients with sickle cell disease.
Topics: Adult; Anemia, Sickle Cell; Antisickling Agents; Blood Pressure; Cause of Death; Drug Resistance; Ec | 2004 |
Pulmonary hypertension as a risk factor for death in patients with sickle cell disease.
Topics: Adult; Anemia, Sickle Cell; Antisickling Agents; Blood Pressure; Cause of Death; Drug Resistance; Ec | 2004 |
Pulmonary hypertension as a risk factor for death in patients with sickle cell disease.
Topics: Adult; Anemia, Sickle Cell; Antisickling Agents; Blood Pressure; Cause of Death; Drug Resistance; Ec | 2004 |
Pulmonary hypertension as a risk factor for death in patients with sickle cell disease.
Topics: Adult; Anemia, Sickle Cell; Antisickling Agents; Blood Pressure; Cause of Death; Drug Resistance; Ec | 2004 |
Pulmonary hypertension as a risk factor for death in patients with sickle cell disease.
Topics: Adult; Anemia, Sickle Cell; Antisickling Agents; Blood Pressure; Cause of Death; Drug Resistance; Ec | 2004 |
Pulmonary hypertension as a risk factor for death in patients with sickle cell disease.
Topics: Adult; Anemia, Sickle Cell; Antisickling Agents; Blood Pressure; Cause of Death; Drug Resistance; Ec | 2004 |
Pulmonary hypertension as a risk factor for death in patients with sickle cell disease.
Topics: Adult; Anemia, Sickle Cell; Antisickling Agents; Blood Pressure; Cause of Death; Drug Resistance; Ec | 2004 |
Pulmonary hypertension as a risk factor for death in patients with sickle cell disease.
Topics: Adult; Anemia, Sickle Cell; Antisickling Agents; Blood Pressure; Cause of Death; Drug Resistance; Ec | 2004 |
Pulmonary hypertension as a risk factor for death in patients with sickle cell disease.
Topics: Adult; Anemia, Sickle Cell; Antisickling Agents; Blood Pressure; Cause of Death; Drug Resistance; Ec | 2004 |
Pulmonary hypertension as a risk factor for death in patients with sickle cell disease.
Topics: Adult; Anemia, Sickle Cell; Antisickling Agents; Blood Pressure; Cause of Death; Drug Resistance; Ec | 2004 |
Pulmonary hypertension as a risk factor for death in patients with sickle cell disease.
Topics: Adult; Anemia, Sickle Cell; Antisickling Agents; Blood Pressure; Cause of Death; Drug Resistance; Ec | 2004 |
Pulmonary hypertension as a risk factor for death in patients with sickle cell disease.
Topics: Adult; Anemia, Sickle Cell; Antisickling Agents; Blood Pressure; Cause of Death; Drug Resistance; Ec | 2004 |
Pulmonary hypertension as a risk factor for death in patients with sickle cell disease.
Topics: Adult; Anemia, Sickle Cell; Antisickling Agents; Blood Pressure; Cause of Death; Drug Resistance; Ec | 2004 |
Pulmonary hypertension as a risk factor for death in patients with sickle cell disease.
Topics: Adult; Anemia, Sickle Cell; Antisickling Agents; Blood Pressure; Cause of Death; Drug Resistance; Ec | 2004 |
Pulmonary hypertension as a risk factor for death in patients with sickle cell disease.
Topics: Adult; Anemia, Sickle Cell; Antisickling Agents; Blood Pressure; Cause of Death; Drug Resistance; Ec | 2004 |
Pulmonary hypertension as a risk factor for death in patients with sickle cell disease.
Topics: Adult; Anemia, Sickle Cell; Antisickling Agents; Blood Pressure; Cause of Death; Drug Resistance; Ec | 2004 |
Pulmonary hypertension as a risk factor for death in patients with sickle cell disease.
Topics: Adult; Anemia, Sickle Cell; Antisickling Agents; Blood Pressure; Cause of Death; Drug Resistance; Ec | 2004 |
Pulmonary hypertension as a risk factor for death in patients with sickle cell disease.
Topics: Adult; Anemia, Sickle Cell; Antisickling Agents; Blood Pressure; Cause of Death; Drug Resistance; Ec | 2004 |
Pulmonary hypertension as a risk factor for death in patients with sickle cell disease.
Topics: Adult; Anemia, Sickle Cell; Antisickling Agents; Blood Pressure; Cause of Death; Drug Resistance; Ec | 2004 |
Pulmonary hypertension as a risk factor for death in patients with sickle cell disease.
Topics: Adult; Anemia, Sickle Cell; Antisickling Agents; Blood Pressure; Cause of Death; Drug Resistance; Ec | 2004 |
Pulmonary hypertension as a risk factor for death in patients with sickle cell disease.
Topics: Adult; Anemia, Sickle Cell; Antisickling Agents; Blood Pressure; Cause of Death; Drug Resistance; Ec | 2004 |
Pulmonary hypertension as a risk factor for death in patients with sickle cell disease.
Topics: Adult; Anemia, Sickle Cell; Antisickling Agents; Blood Pressure; Cause of Death; Drug Resistance; Ec | 2004 |
Pulmonary hypertension as a risk factor for death in patients with sickle cell disease.
Topics: Adult; Anemia, Sickle Cell; Antisickling Agents; Blood Pressure; Cause of Death; Drug Resistance; Ec | 2004 |
Pulmonary hypertension as a risk factor for death in patients with sickle cell disease.
Topics: Adult; Anemia, Sickle Cell; Antisickling Agents; Blood Pressure; Cause of Death; Drug Resistance; Ec | 2004 |
Pulmonary hypertension as a risk factor for death in patients with sickle cell disease.
Topics: Adult; Anemia, Sickle Cell; Antisickling Agents; Blood Pressure; Cause of Death; Drug Resistance; Ec | 2004 |
Pulmonary hypertension as a risk factor for death in patients with sickle cell disease.
Topics: Adult; Anemia, Sickle Cell; Antisickling Agents; Blood Pressure; Cause of Death; Drug Resistance; Ec | 2004 |
Pulmonary hypertension as a risk factor for death in patients with sickle cell disease.
Topics: Adult; Anemia, Sickle Cell; Antisickling Agents; Blood Pressure; Cause of Death; Drug Resistance; Ec | 2004 |
Pulmonary hypertension as a risk factor for death in patients with sickle cell disease.
Topics: Adult; Anemia, Sickle Cell; Antisickling Agents; Blood Pressure; Cause of Death; Drug Resistance; Ec | 2004 |
Pulmonary hypertension as a risk factor for death in patients with sickle cell disease.
Topics: Adult; Anemia, Sickle Cell; Antisickling Agents; Blood Pressure; Cause of Death; Drug Resistance; Ec | 2004 |
Pulmonary hypertension as a risk factor for death in patients with sickle cell disease.
Topics: Adult; Anemia, Sickle Cell; Antisickling Agents; Blood Pressure; Cause of Death; Drug Resistance; Ec | 2004 |
Pulmonary hypertension as a risk factor for death in patients with sickle cell disease.
Topics: Adult; Anemia, Sickle Cell; Antisickling Agents; Blood Pressure; Cause of Death; Drug Resistance; Ec | 2004 |
Pulmonary hypertension as a risk factor for death in patients with sickle cell disease.
Topics: Adult; Anemia, Sickle Cell; Antisickling Agents; Blood Pressure; Cause of Death; Drug Resistance; Ec | 2004 |
Pulmonary hypertension as a risk factor for death in patients with sickle cell disease.
Topics: Adult; Anemia, Sickle Cell; Antisickling Agents; Blood Pressure; Cause of Death; Drug Resistance; Ec | 2004 |
Pulmonary hypertension as a risk factor for death in patients with sickle cell disease.
Topics: Adult; Anemia, Sickle Cell; Antisickling Agents; Blood Pressure; Cause of Death; Drug Resistance; Ec | 2004 |
Pulmonary hypertension as a risk factor for death in patients with sickle cell disease.
Topics: Adult; Anemia, Sickle Cell; Antisickling Agents; Blood Pressure; Cause of Death; Drug Resistance; Ec | 2004 |
Pulmonary hypertension as a risk factor for death in patients with sickle cell disease.
Topics: Adult; Anemia, Sickle Cell; Antisickling Agents; Blood Pressure; Cause of Death; Drug Resistance; Ec | 2004 |
Pulmonary hypertension as a risk factor for death in patients with sickle cell disease.
Topics: Adult; Anemia, Sickle Cell; Antisickling Agents; Blood Pressure; Cause of Death; Drug Resistance; Ec | 2004 |
Pulmonary hypertension as a risk factor for death in patients with sickle cell disease.
Topics: Adult; Anemia, Sickle Cell; Antisickling Agents; Blood Pressure; Cause of Death; Drug Resistance; Ec | 2004 |
Treatment of sickle cell anemia with hydroxyurea and erythropoietin.
Topics: Administration, Oral; Anemia, Sickle Cell; Drug Administration Schedule; Drug Evaluation; Drug Thera | 1990 |
The X-Y-Z scheme of immunocyte maturation. VII. Cell division and the establishment of short-term IgM memory.
Topics: Animals; Antigen-Antibody Reactions; Antigens; Cell Division; Erythrocytes; Female; Hemolysis; Hydro | 1969 |